Meet IAG’ Research Team at OARSI to Discuss Osteoarthritis Clinical Research

Meet IAG’ Research Team at OARSI to Discuss Osteoarthritis Clinical Research

Meet IA’s musculoskeletal experts at the World Congress on Osteoarthritis in Las Vegas, NV, April 27-30, 2017, where they will be speaking about their work in osteoarthritis clinical research.

Dr. John Carrino, member of IA’s Clinical Advisory Board will speak at 12:00 on 30 April in a Plenary Session ‘Year in Review’ and give an overview of imaging in Osteoarthritis clinical practice and research.

The Chair of IAG’s Clinical Advisory Board Dr. Mikael Boesen will present a paper linking the exercise and pain reductions in knee osteoarthritis. His presentation ‘Exercise-Induced Pain Reductions in Knee OA are Associated with Changes in Muscle Perfusion Quantified by Dynamic Contrast Enhanced MRI: Exploratory Outcome Analysis from a Randomized Controlled Trial’ is scheduled to start at 4:40pm on Saturday, 29 April.

Other collaborators of IAG from the Parker Institute, Nordic Bioscience, BICL and Boston University will be attending OARSI, which brings together the top researchers, investigators and investors trying to find cure for osteoarthritis.

About Osteoarthritis

Osteoarthritis is a degenerative joint disease and the most common disorder in the world. It is a result of a complex interplay of multiple factors, including joint integrity, genetic predisposition, local inflammation, mechanical forces and cellular and biochemical processes. There is no cure for OA at the moment.

About IAG

IAG is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. Our dynamic Strategy, Trial Solutions and Bio-Partnering divisions work closely to meet critical needs of biotechnology companies: funding, clinical development and monetization of their assets. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed. www.ia-grp.com

E: contact@ia-grp.com

T: + 44 74 13 02 20 53 / + 1 6177 523561

W: www.ia-grp.com

News
Events